LGC initiates European trial of genotyping technology
The company also reported that the first patient within the trial has been successfully genotyped and treatment has been initiated. LGC is collaborating with researchers from six European
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.